ARISTOTLE

• Research type

  Research Study

• Full title

  ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.

• IRAS ID

  5406

• Contact name

  David Sebag-Montefiore

• Sponsor organisation

  Joint UCL/UCLH/RFH Biomedical Research Unit

• Eudract number

  2008-005782-59

• ISRCTN Number

  ISRCTN09351447

• Research summary

  There is evidence to suggest some patients with rectal cancer benefit from receiving chemotherapy and radiotherapy before they have an operation to remove their cancer. The ARISTOTLE trial aims to investigate whether the addition of a second drug (irinotecan) to the standard treatment of chemoradiotharpy (oral chemotherapy (capecitabine) and radiotherapy) will result in fewer cancer recurrences (regrowth) after the operation and if patients live longer. The trial aims to recruit 920 patients over 5 years with MRI-defined locally advanced non metastatic rectal cancer from about 40 centres in the UK.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  10/H0706/65

• Date of REC Opinion

  29 Sep 2010

• REC opinion

  Favourable Opinion